论文部分内容阅读
通过血凝抑制试验测定的抗体滴度与抗流感病毒感染保护作用是相关联的,并且被用来作为疫苗审批的特定指标。在一项有773名6-17岁儿童参与的随机有对照的季节性流感疫苗接种的现场试验中,作者评估了1∶40的抗A(H1N1)pdm09和B(Victoria谱系)的血凝抑制(HAI)滴度与抗每一株引起的由PCR确证感染的保护相关,抗前者的保护
Antibody titers, as determined by the hemagglutination inhibition test, correlate with protection against influenza virus infection and are used as a specific indicator of vaccine approval. In a field trial of randomized controlled seasonal influenza vaccination with 773 children aged 6-17 years, the authors evaluated the hemagglutination inhibition of 1:40 anti-A (H1N1) pdm09 and B (Victoria pedigree) (HAI) titers were associated with protection against PCR-confirmed infections caused by each strain, protection against the former